Dermatology Research
Vitiligo Study
Investigating the Efficacy, Safety, and Tolerability of Ritlecitinib in Adult and Adolescent Participants with Non-Segmental Vitiligo
AGE: 18+ years old
SEX AT BIRTH: All
SEX AT BIRTH: All
TYPE: Interventional Study
CONDITION: Vitiligo
CONDITION: Vitiligo
HEALTHY PARTICIPANTS: No
LOCATION: University Hospitals Cleveland Medical Center
LOCATION: University Hospitals Cleveland Medical Center
Learn More About This Research Study
For more information, please contact study coordinator, Kymberlyn Warner King at 216-844-7546 or complete the form below.
Study Purpose
The purpose of the study is to evaluate whether the study drug, Ritlecitinib, is effective in managing vitiligo and if it is safe for human use. The study drug will be compared with a placebo, a study drug that does not contain any active ingredients, to find out if the study drug is better than the placebo for the study treatment of vitiligo.
Who Can Participate
Participants 18 years and older diagnosed with non-segmental vitiligo may be eligible for this study.